Nanexa

Nanexa P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Nanexa (NANEXA.ST) as of Oct 23, 2026 is -22.10. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -10.62 — a change of 108.13% (lower).

P/FCF

-22.10

YoY

108.13%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Nanexa is 2025 -22.10 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Nanexa was 2024 -10.62 . It decreases by 108.13% lower compared to the previous year.

The Nanexa P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-43.44 SEK
Jan 1, 2019
-28.85 SEK
Jan 1, 2020
-15.39 SEK
Jan 1, 2021
-11.37 SEK
Jan 1, 2022
-13.38 SEK
Jan 1, 2023
-7.53 SEK
Jan 1, 2024
-10.62 SEK
Jan 1, 2025
-22.10 SEK
The Nanexa P/FCF history
YEARP/FCFYoY
-22.10+108.13%
-10.62+40.98%
-7.53-43.71%
-13.38+17.61%
-11.37-26.10%
-15.39-46.66%
-28.85-33.58%
-43.44-13.49%
-50.22-23.23%
-65.42-43.09%
-114.94-111.19%
1,026.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanexa Stock analysis

What does Nanexa do? Nanexa AB develops and distributes medical nanotechnology products including PharmaShell, a drug delivery system for targeted dosing, and antifungal coating that protects medical products from fungal growth. The company also offers low-friction coating for peripheral venous catheters. Its products are sold to healthcare providers and medical device manufacturers seeking advanced solutions for drug delivery and infection prevention. Nanexa AB's revenue comes from the sale of its nanotechnology-based products to healthcare institutions and medical device companies. The firm focuses on life science R&D, targeting applications in pharmaceuticals and medical device manufacturing. Its product portfolio serves the healthcare sector by enhancing drug efficacy and protecting medical equipment from microbial contamination. The company's business model relies on selling specialized coatings and delivery systems to medical professionals and manufacturers. PharmaShell enables precise drug targeting, while antifungal and low-friction coatings address specific clinical needs in medical device usage. These products are designed to improve patient outcomes and reduce complications in medical treatments. Nanexa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanexa stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Nanexa is -22.10 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Nanexa changed from -10.62 to -22.10, representing a 108.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Nanexa since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Nanexa with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Nanexa

All Key Metrics — Nanexa